Trump's new tariff move may raise U.S. pharma costs, with analysts warning of risks tied to EU manufacturing and shifting healthcare policies.

Drugmaker stocks gained a temporary reprieve on Thursday as U.S. President Donald Trump spared pharmaceutical products from ...

As companies call employees back to the office, many are now offering innovative perks like ‘recharge days’ to help ease the ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Vertex Pharmaceuticals (VRTX – Research Report) and Apellis ...

Bank of America upped its price target for Vertex Pharmaceuticals from $555 to $567, signaling growing confidence in the ...

SpotDraft, an AI-driven contract lifecycle management (CLM) platform for in-house legal teams, raised $54 million in Series B funding led by Vert ...

RBC Capital raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $420 from $408 and keeps a Sector Perform rating on the shares.

This marks an 8% increase over the amount invested during the same period in 2024, and a slight 1% decline compared to the ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $478.12, a high ...

Eli Lilly Weight Loss Drug: India's obesity crisis is intensifying, with big pharma companies like Eli Lilly and Novo Nordisk competing to introduce weight-loss drugs in the market. The economic ...

American pharmaceutical major Eli Lilly and Company on Thursday (March 20, 2025) launched its diabetes and obesity management drug Mounjaro (tirzepatide) in India. The company launched the drug in ...

With diabetes and obesity cases surging in India, pharmaceutical giant Eli Lilly and Company (India) has launched Mounjaro (tirzepatide), a once-weekly injectable drug for chronic weight ...